Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

[1]  N. Puig,et al.  Measurable residual disease in multiple myeloma: ready for clinical practice? , 2020, Journal of Hematology & Oncology.

[2]  D. Madduri,et al.  Selinexor in relapsed/refractory multiple myeloma , 2020, Therapeutic advances in hematology.

[3]  O. Tsitsilonis,et al.  Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches , 2020, Frontiers in Oncology.

[4]  Gordon Cook,et al.  Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) , 2020, Leukemia.

[5]  P. Neri,et al.  Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities , 2020, Frontiers in Oncology.

[6]  T. Willis,et al.  Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. , 2018, Blood.

[7]  ClonoSEQ Cleared for Residual Cancer Testing. , 2018, Cancer discovery.

[8]  M. Dimopoulos,et al.  Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX , 2018, Haematologica.

[9]  P. Sonneveld,et al.  Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR , 2018, Haematologica.

[10]  Andre H Crepaldi,et al.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma , 2017, The New England journal of medicine.

[11]  A. Dispenzieri,et al.  High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma , 2017, Blood Cancer Journal.

[12]  H. Goldschmidt,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[14]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[15]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[16]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[17]  Bie M. P. Verbist,et al.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.

[18]  T. Plesner,et al.  Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference , 2016, Clinical chemistry and laboratory medicine.

[19]  B. Pégourié,et al.  VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. , 2016, Blood.

[20]  S. Lonial,et al.  Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. , 2015, Blood.

[21]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Beksac,et al.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014, Haematologica.

[23]  D. Dingli,et al.  Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Morgan,et al.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  B. Pégourié,et al.  Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma , 2013, Leukemia.

[26]  T. Kalina,et al.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.

[27]  A. Oriol,et al.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. , 2012, Blood.

[28]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[29]  B. Pégourié,et al.  Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. , 2011, Blood.

[30]  M. Baccarani,et al.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study , 2010, The Lancet.

[31]  J. Vose,et al.  NCCN clinical practice guidelines in oncology: multiple myeloma. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  A. Órfão,et al.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. , 2008, Blood.

[33]  Yuliya Lokhnygina,et al.  Cox Regression Methods for Two‐Stage Randomization Designs , 2007, Biometrics.